Phase 2 Irritable Bowel Syndrome Trial, Recruiting (NCT07545772)

Phase 2 Irritable Bowel Syndrome Trial, Recruiting NCT07545772 Sponsor: Eli Lilly and Company Condition: Irritable Bowel Syndrome

Printed from Voxsanity (voxsanity.com.au) — NCT07545772 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Irritable Bowel Syndrome

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a type of irritable bowel syndrome that mainly causes constipation (IBS-C), where most of your stools are hard or lumpy and very few are loose or watery
During a screening period before the trial starts, you kept a daily diary showing that your worst stomach pain averaged at least 3 out of 10 over 14 days in a row

Who may not be able to join:

You have a type of irritable bowel syndrome that mainly causes diarrhea, a mix of diarrhea and constipation, or a type that does not fit clearly into one category
You have been diagnosed with an inflammatory or immune-related condition affecting your digestive system (confirm with trial site)
You have a known problem with the way your stomach empties food into your intestines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07545772

Sponsor: Eli Lilly and Company

Phase: Phase 2

Status: Recruiting

Condition: Irritable Bowel Syndrome

Trial contact: 1-317-615-4559

More information: https://clinicaltrials.gov/study/NCT07545772

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a type of irritable bowel syndrome that mainly causes constipation (IBS-C), where most of your stools are hard or lumpy and very few are loose or watery
During a screening period before the trial starts, you kept a daily diary showing that your worst stomach pain averaged at least 3 out of 10 over 14 days in a row

Who may not be able to join:

You have a type of irritable bowel syndrome that mainly causes diarrhea, a mix of diarrhea and constipation, or a type that does not fit clearly into one category
You have been diagnosed with an inflammatory or immune-related condition affecting your digestive system (confirm with trial site)
You have a known problem with the way your stomach empties food into your intestines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Eli Lilly and Company

Registry

ClinicalTrials.gov

Start date

29 April 2026

Est. completion

1 July 2027

Where this trial is recruiting

🇧🇪 Belgium 🇨🇦 Canada 🇨🇳 China 🇯🇵 Japan 🇲🇽 Mexico 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov